KR20220098082A - 종양 감소 제형 및 그의 사용 방법 - Google Patents

종양 감소 제형 및 그의 사용 방법 Download PDF

Info

Publication number
KR20220098082A
KR20220098082A KR1020217003523A KR20217003523A KR20220098082A KR 20220098082 A KR20220098082 A KR 20220098082A KR 1020217003523 A KR1020217003523 A KR 1020217003523A KR 20217003523 A KR20217003523 A KR 20217003523A KR 20220098082 A KR20220098082 A KR 20220098082A
Authority
KR
South Korea
Prior art keywords
composition
acid
tumor
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217003523A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 호프만
존 롯만
Original Assignee
타임, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타임, 인크. filed Critical 타임, 인크.
Publication of KR20220098082A publication Critical patent/KR20220098082A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020217003523A 2018-07-09 2019-07-02 종양 감소 제형 및 그의 사용 방법 Withdrawn KR20220098082A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
US62/695,613 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20220098082A true KR20220098082A (ko) 2022-07-11

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003523A Withdrawn KR20220098082A (ko) 2018-07-09 2019-07-02 종양 감소 제형 및 그의 사용 방법

Country Status (11)

Country Link
EP (1) EP3820482A4 (https=)
JP (1) JP2021530482A (https=)
KR (1) KR20220098082A (https=)
CN (1) CN112584841A (https=)
AU (1) AU2019309757A1 (https=)
BR (1) BR112021000279A8 (https=)
CA (1) CA3105717A1 (https=)
EA (1) EA202190201A1 (https=)
IL (1) IL280000A (https=)
PH (1) PH12021550033A1 (https=)
WO (1) WO2020023191A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220152051A1 (en) * 2019-03-15 2022-05-19 Dalian University Application of glycocholic acid in preparation of antitumor drugs
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US20210169903A1 (en) * 2019-12-09 2021-06-10 Tyme, Inc. Pharmaceutical compositions and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202094A1 (en) * 2004-01-29 2005-09-15 Werling Jane O. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2016007741A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
EP3429583A1 (en) * 2016-03-15 2019-01-23 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Also Published As

Publication number Publication date
CA3105717A1 (en) 2020-01-30
IL280000A (en) 2021-03-01
AU2019309757A1 (en) 2021-03-04
EA202190201A1 (ru) 2021-04-09
BR112021000279A2 (pt) 2021-04-06
EP3820482A4 (en) 2022-03-23
WO2020023191A1 (en) 2020-01-30
PH12021550033A1 (en) 2021-09-20
JP2021530482A (ja) 2021-11-11
CN112584841A (zh) 2021-03-30
BR112021000279A8 (pt) 2021-04-20
CN112584841A8 (zh) 2021-06-18
EP3820482A1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
CN108464981B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
KR20220098082A (ko) 종양 감소 제형 및 그의 사용 방법
US9457019B2 (en) Methods for inhibiting tie-2 kinase useful in the treatment of cancer
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
KR20180021697A (ko) 암 치료
WO2017117196A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
BR112019009799A2 (pt) método para tratar câncer em um paciente
WO2021129616A1 (zh) 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN106456572A (zh) 用于增加mhc‑i表达的姜黄根醇化合物
US20210275467A1 (en) Tumor reduction formulations and methods of use thereof
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2025513929A (ja) がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ
WO2014165853A1 (en) Inhibitors of metastasis
KR101824205B1 (ko) 암 예방 또는 치료용 약학적 조성물 및 이의 용도
EP4065108B1 (en) Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP2021533107A (ja) 癌を治療するための併用療法
KR102870154B1 (ko) 암의 전이 억제 및 치료용 조성물
WO2018088933A1 (en) Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
KR20190094765A (ko) 암의 전이 억제 및 치료용 조성물
JP2018524292A (ja) オーロラキナーゼインヒビターと化学療法剤の投与
HK1257617B (en) Use of a composition for inhibiting tie2 kinase in the manufacture of a medicament for treating cancer
HK1257617A1 (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
WO2024204679A1 (ja) 抗ＣＤＨ６抗体－薬物コンジュゲートとＨＩＦ－２α阻害剤の組み合わせ

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202